Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
Entrectinib: first global approval
ZT Al-Salama, SJ Keam - Drugs, 2019 - Springer
Entrectinib (Rozlytrek®) is an oral selective inhibitor of the tyrosine kinases tropomyosin
receptor kinases (Trk) A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase …
receptor kinases (Trk) A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase …
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
JE Frampton - Drugs, 2021 - Springer
Entrectinib (Rozlytrek®) is an orally active, CNS-penetrant, small-molecule, selective
inhibitor of the tropomyosin receptor tyrosine kinases TRKA/B/C [encoded by the …
inhibitor of the tropomyosin receptor tyrosine kinases TRKA/B/C [encoded by the …
Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
L Mayr, AS Guntner, S Madlener, MT Schmook… - Journal of Personalized …, 2020 - mdpi.com
Targeting oncogenic fusion-genes in pediatric high-grade gliomas (pHGG) with entrectinib
has emerged as a highly promising therapeutic approach. Despite ongoing clinical studies …
has emerged as a highly promising therapeutic approach. Despite ongoing clinical studies …
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
Entrectinib (ENC) is a potent orally available anaplastic lymphoma kinase (ALK) inhibitor. In
10 July 2017, biotechnology company (Ignyta) announced that granted orphan drug …
10 July 2017, biotechnology company (Ignyta) announced that granted orphan drug …
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
PP Segura, NV Quintela, MM García… - Clinical and …, 2023 - Springer
High-grade gliomas (HGG) are the most common primary brain malignancies and account
for more than half of all malignant primary brain tumors. The new 2021 WHO classification …
for more than half of all malignant primary brain tumors. The new 2021 WHO classification …
LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: in vivo and in vitro metabolic investigation
Abstract Entrectinib (RXDX-101) is orally available inhibitor of the tyrosine kinases including
tropomyosin receptor kinases (Trk) A–C, C-ros oncogene 1 (ROS1) and anaplastic …
tropomyosin receptor kinases (Trk) A–C, C-ros oncogene 1 (ROS1) and anaplastic …
Brain metastases in lung cancers with emerging targetable fusion drivers
The management of non-small cell lung cancer (NSCLC) has transformed with the discovery
of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene …
of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene …
Molecular evolution of central nervous system metastasis and therapeutic implications
D Gritsch, PK Brastianos - Trends in Molecular Medicine, 2024 - cell.com
The increasing prevalence and poor prognosis of central nervous system (CNS) metastases
pose a significant challenge in oncology, necessitating improved therapeutic strategies …
pose a significant challenge in oncology, necessitating improved therapeutic strategies …
Evaluating entrectinib as a treatment option for non-small cell lung cancer
J Lee, S Park, HA Jung, JM Sun, SH Lee… - Expert opinion on …, 2020 - Taylor & Francis
Introduction Entrectinib, an oral pan-TRK, ALK, and ROS1 inhibitor is approved as a first-line
treatment for NTRK-rearranged solid tumors and ROS1-rearranged non-small cell lung …
treatment for NTRK-rearranged solid tumors and ROS1-rearranged non-small cell lung …